On June 29, 2020, Zhang Yu, director of the production Supervision Department of Shaanxi Provincial Drug Administration, and his party visited our company to conduct research and guidance on the related problems encountered by APIs under the new policy to help enterprises solve practical difficulties. Wang Peiwen, vice general manager of the company, and Hou Liying, the person in charge of quality, received and accompanied him.

At the forum, Wang Peiwen, deputy general manager of our company, and Hou Liying, the person in charge of quality, first introduced the general situation of the company, new product research and development plan, etc., focusing on the fact that the dexamethasone product produced by our company has been confirmed by British RECOVERY clinical research in COVID-19 's treatment, which has become a drug to save the death of severe COVID-19 patients. Subsequently, he accompanied Zhang and other three experts to conduct on-the-spot visits to the quality and production sites, and communicated in detail the management and control of drug quality and safety in the company. Zhang fully affirmed the standardized management of the enterprise's GMP.

During the research, Zhang carefully inquired about the congestion points encountered by enterprises under the new policy and the problems that needed to be solved urgently, and gave corresponding answers. Zhang said that the provincial drug regulatory bureau attaches great importance to the development of API manufacturers, and the provincial bureau is willing to give enterprises one-to-one assistance services to help enterprises develop better.

Division I will continue to uphold the concept of "survival by quality, development by management", strictly abide by GMP management standards,
and ensure the quality, safety, stability and control of drug production.

Xi'an Guokang Ruijin Pharmaceutical Co.,Ltd.
June 29, 2020